Comparing SG&A Expenses: Pfizer Inc. vs Soleno Therapeutics, Inc. Trends and Insights

SG&A Expenses: A Tale of Two Companies

In the world of pharmaceuticals and therapeutics, the Selling, General, and Administrative (SG&A) expenses are a crucial indicator of a company's operational efficiency. Over the past decade, Pfizer Inc. and Soleno Therapeutics, Inc. have shown contrasting trends in their SG&A expenses.

Pfizer Inc.: A Steady Giant

From 2014 to 2023, Pfizer's SG&A expenses have remained relatively stable, averaging around $14 billion annually. Despite a dip in 2020, likely due to global economic shifts, Pfizer's expenses rebounded by 2023, reflecting a robust recovery strategy.

Soleno Therapeutics, Inc.: A Growing Contender

In contrast, Soleno Therapeutics, Inc. has seen a significant increase in SG&A expenses, growing by over 360% from 2014 to 2023. This rise indicates an aggressive expansion strategy, as the company invests in marketing and administrative capabilities to enhance its market presence.

These trends highlight the strategic differences between an established pharmaceutical leader and an emerging therapeutic innovator.